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SUMMARY
Functional imaging studies complement struc-
tural magnetic resonance imaging (MRI) in the
assessment of patients with brain tumor–associ-
ated focal epilepsy. 11C-Methionine (MET) and
18F-fluoro-ethyl-L-tyrosine (FET) are amino acid
analogues that highlightmetabolically active areas
in positron emission tomography (PET). Ictal sin-
gle photon emission computed tomography
(SPECT) can provide information about perile-
sional areas of seizure onset and early propaga-
tion. Functional MRI (fMRI) and diffusion tensor
imaging (DTI) allow noninvasive identification of
potentially eloquent motor, sensory, and language
cortical areas and pathways with an accuracy of
10–15 mm compared to electrocortical stimula-
tion (ECS). Repetitive navigated transcranial mag-
netic stimulation (TMS) allows even more precise
noninvasive delineation of primary motor cortex.
Information from functional imaging studies helps
in the planning of brain tumor biopsies, resections,
and the planning of intracranial video–electroen-
cephalography (EEG) studies.
KEY WORDS: Tumoral epilepsy, Positron emis-
sion tomography, Ictal SPECT, Functional MRI,
Navigated transcranial magnetic stimulation.
Patients with pharmacoresistant focal epilepsy in the
setting of brain tumors are unique in that the morphol-
ogy of the tumor, its expected behavior over time, and
epilepsy-related morbidity need to be taken into account
in the decision-making process. In this setting, func-
tional imaging studies may fulfill several purposes, and
these can be categorized according to different questions
that can arise in the management of such patients
(Table 1).
Functional Imaging to Evaluate
the Morphology of Brain
Tumor Tissue
Although structural magnetic resonance imaging
(MRI) with and without gadolinium allows precise iden-
tification of the brain tumor, its limitations need to be
recognized. Dysembryoplastic neuroepithelial tumors
(DNTs) and gangliogliomas are the most common forms
of low grade brain neoplasms encountered in
patients with refractory focal epilepsy. Structural MRI
currently does not distinguish these in all cases from
focal cortical dysplasia (FCD). Gadolinium enhance-
ment reflects breakdown of the blood–brain barrier.
However, changes in gadolinium enhancement may not
provide adequate information with regard to changes in
tumor morphology over time. In particular, it does not
help to differentiate between radiation-induced necrosis
and tumor progression. In this context, “pseudoregres-
sion” refers to a situation where gadolinium enhancement
diminishes over time, although the tumor does not shrink
significantly. Conversely, “pseudoprogression” reflects
an increase in gadolinium enhancement that is not
mirrored by disease progression. Functional imaging
techniques can complement structural MRI to address
these questions.
Positron emission tomography (PET) utilizes
radioactively labeled analogues of glucose, amino acid, or
nucleotide metabolism to visualize metabolic aspects of a
brain lesion. Compared to 18F-fluorodeoxyglucose (FDG),
the most commonly used agent in epilepsy, 11C-methionine
(MET) and 18F-fluoro-ethyl-L-tyrosine (FET) may be more
specific for brain tumor tissue. Although they provide
comparable diagnostic information, the short half-life of
MET (20 min) requires a cyclotron on site (Grosu et al.,
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2011). FET (half-life 120 min) does not have this limita-
tion, which makes it more practical in the clinical setting
(Rapp et al., 2013).
A recent large series (Hutterer et al., 2013) charac-
terized the uptake of FET in 393 patients with a vari-
ety of central nervous system (CNS) pathologies
(neoplastic, inflammatory, and others). Structural MRI
with gadolinium was available in all patients, and
80% of patients underwent resection or biopsy, result-
ing in histopathology data available for comparison. In
this largest series to date, 79% of low grade glioma
(World Health Organization [WHO] grade I or II) and
96% of high grade glioma (WHO grade III and IV)
had increased FET uptake. Seventy-two percent of
tumors without gadolinium enhancement expressed an
increase in FET, compared to 97% of those with gad-
olinium enhancement. However, FET uptake was also
increased in a variety of nonneoplastic lesions, includ-
ing hippocampal sclerosis (33%), FCD (32%), cavern-
ous angioma (63%), as well as inflammatory lesions
and nonglial brain tumors (Hutterer et al., 2013).
Therefore, results of FET PET need to be interpreted
in conjunction with standard MRI. One useful clinical
application of FET is the identification of metaboli-
cally active tumor regions when planning a biopsy
(Rapp et al., 2013). Of interest, MET uptake is lower
in DNTs compared to other low grade and high grade
brain neoplasms (Maehara et al., 2004; Rosenberg
et al., 2005). In seven patients with pharmacoresistant
temporal lobe epilepsy in the setting of low grade
brain tumors, MET uptake was low in the four
patients with histopathologically confirmed DNT, and
high in the three patients with ganglioglioma, low
grade astrocytoma, and pleomorphic astrocytoma
(Maehara et al., 2004). These results were confirmed
in a larger sample of temporal and extratemporal low
grade brain tumors associated with pharmacoresistant
epilepsy. MET uptake was moderate or high in all 16
gangliogliomas and low grade gliomas, and low
(n = 7, including all six mesial temporal DNTs) or
moderate (n = 4) in all DNTs (Rosenberg et al.,
2005). An increase in MET uptake thus makes a diag-




Ictal single photon emission computed tomography
(SPECT) provides a functional imaging correlate of the
zone of seizure onset and early ictal propagation. Most
centers utilize it in MRI-negative patients or in those
where structural imaging and video-EEG provide discor-
dant information. In this setting, ictal SPECT may allow
the bypassing of intracranial recordings. For example, if it
can provide further support for localizing perilesional sei-
zure onset in patient with unusual ictal semiology and/or
nonlocalizing EEG findings (Fig. 1). Four series have
examined the contribution of ictal SPECT in the presurgi-
cal evaluation of patients with focal epilepsy to date (Ahn-
lide et al., 2007; Rathore et al., 2011; Lee et al., 2011;
Von Oertzen et al., 2012). Only 14 (5.5%) of 253 patients
in these series had brain neoplasms, and it is unknown
whether the yield of ictal SPECT in this setting is different
from that of patients with other MRI-detectable pathology
or nonlesional cases.
One potential indication for nuclear medicine studies in
the presurgical evaluation of patients with refractory focal
epilepsy and low grade brain tumors is the identification
of tumor-associated MRI-negative FCD. In a study of nine
patients with temporal lobe DNTs, hyperperfusion on ictal
SPECT was restricted to the mass lesion in three patients
without associated FCD. In six patients with DNT-associ-
ated FCD, the area of hyperperfusion was more extensive
and included perilesional areas that appeared normal on
MRI (Valenti et al., 2002). The epileptogenic zone may
extend beyond the MR-visible lesion in the nodular-like
and dysplastic/diffuse subtypes of DNTs (Chassoux et al.,
2012), and DNT-associated areas of FCD are frequently
implicated in seizure generation. Advances in structural
and functional imaging might allow identification of
tumor-associated areas of FCD noninvasively, which in
turn could help to delineate the resection margins or even
eliminate the need for intracranial EEG recordings in
some patients.
Functional Imaging in the
Identification of Eloquent
Areas
Functional MRI (fMRI) is widely used in preopera-
tive planning, both for resection of tumors and prior to
intracranial EEG. Motor fMRI utilizing finger tapping,
toe wiggling, or tongue movements allows identifica-
Table 1. Functional imaging studies utilized in
the evaluation of patients with focal epilepsy in
the setting of brain tumors
Functional imaging
modality
Tumor morphology MRI, MRS, PET
Tumor recurrence vs. treatment response vs.
iatrogenic changes
MRI, PET
Relationship of tumor to ictal onset zone Ictal SPECT
Relationship of tumor to eloquent cortical
areas or pathways
fMRI, DTI, TMS
MRS, magnetic resonance spectroscopy.
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tion of plausible regions of interest in up to 99% of
patients, and it may thus be superior to reliance on ana-
tomic landmarks (“hand knob” sign and foot sign on
MRI), especially in patients with a neoplastic lesion in
the pericentral area, where distortions may be present
from mass effect (Lehericy et al., 2000; Wengenroth
et al., 2011). Compared to electrocortical stimulation
(ECS), hand motor fMRI had a sensitivity of 88% and
specificity of 87% (Bizzi et al., 2008). The sensitivity
was lower and the specificity higher in patients with
grade IV gliomas compared to those with grade I–III
gliomas.
For language lateralization, fMRI has largely replaced
the intracarotid amobarbital procedure (Wada test, Jan-
ecek et al., 2013). However, fMRI does not allow precise
localization of essential anterior and posterior language
areas. In a study of 14 right-handed patients with
neoplasms originating from the middle or inferior frontal
gyrus on the left (i.e., in the vicinity of the anterior lan-
guage area by anatomical criteria), fMRI had a sensitivity
of 59% and a specificity of 97% compared to intraopera-
tive ECS. One has to keep in mind that the essential elo-
quent anterior language area is often confined to a cortical
region measuring a few square centimeters; the high speci-
ficity in this study was therefore driven by the large num-
ber of areas that were “language silent” both by fMRI and
ECS criteria (Roux et al., 2003). The results of fMRI
depend on statistical analysis (“thresholding”). Changes
in metabolism and neovascularization in the vicinity of a
brain neoplasm reduce the blood oxygen level dependent
(BOLD) effect, which is the fundamental mechanism of




Ictal SPECT in a 38-year-old man with disconcordant imaging and video-EEG findings. Seizures were characterized by
gross hyperkinetic proximal movements of all extremities, facial grimacing, and loss of awareness, followed by late
right-sided manual and oral automatisms. The ictal EEG was nonlocalizing, and there were no interictal epileptiform
discharges. Brain MRI (coronal FLAIR,A, B; axial FLAIR,C,D) shows a mass lesion in the left parahippocampal gyrus
that abuts the hippocampus and extends anteriorly. Ictal SPECT was performed, since neither seizure semiology nor
ictal EEG was suggestive of left mesial temporal onset. Subtraction ictal SPECT coregistered to MRI (SISCOM, B,D)
demonstrates peak hyperperfusion (red) in the left mesial lesion and left hippocampus. Based on this information, the
patient was offered a left temporal resection including the mass lesion and the mesial structures. Pathology revealed
a DNT and mild hippocampal end-folium sclerosis. He has been seizure free postoperatively for 15 months. SISCOM
pictures courtesy of ProfWim van Paesschen, Department of Neurosciences, University of Leuven, Belgium.
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maximal activation may be displaced by one gyrus in the
setting of high grade gliomas and meningiomas. Some
patient cooperation is needed, although successful fMRI
studies have been reported in children as young as 4 years
of age with extensive preparation (Shurtleff et al., 2010).
Areas of activation in fMRI highlight functional networks
involved in a specific task; however, at present they do not
allow precise extraoperative delineation of resection bor-
ders.
DTI approximates white matter tracts based on the
preferred direction of water diffusivity (fractional anisot-
ropy). It thus visualizes pathways that should be pre-
served during surgery, such as Meyer’s loop of the optic
radiation or the corticospinal tract. This information can
be integrated into a neuronavigation system and thus
made intraoperatively available for the neurosurgeon
(Fig. 2). In a study of 28 patients with brain tumors, visu-





Multimodal MRI integration for presurgical planning in a 30-year-old right-handed woman. The patient described an
electrical sensation in the right arm and leg with subsequent generalized convulsions. Structural MRI (A, axial T1 with
Gadolinium; B, coronal FLAIR) demonstrated a low grade tumor in the left postcentral gyrus. (C) Multimodal inte-
gration of structural MRI (lesion manually outlined in red), functional MRI (light green, foot tapping paradigm; dark
green, hand and foot sensory paradigm), and DTI (blue, corticospinal tract) illustrates the proximity of the brain
tumor to eloquent cortical areas and pathways. The patient underwent an awake lesionectomy with intraoperative
electrocorticography. Image courtesy of Dr Roman Rodionov, Department of Clinical and Experimental Epilepsy,
Institute of Neurology, University College London, United Kingdom.
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(Romano et al., 2009). The processing of DTI informa-
tion is user dependent, and perilesional distortions of
normal white matter architecture via compression,
degeneration, and edema can affect the results (Dimou
et al., 2013).
Navigated transcranial magnetic stimulation (TMS) is
a technique that may overcome some of the limitations of
fMRI. It allows extraoperative delivery of magnetic stim-
ulation in precise relation to the patient’s individual
MRI-based gyral anatomy. Its theoretical error (defined
as the discrepancy between maximum stimulus intensity
and area of maximum cortical activation) is in the order
of 6 mm (Ruohonen & Karhu, 2010). Although intense
stimuli may cause some discomfort, most patients report-
edly tolerate the procedure well. Navigated TMS allows
direct identification of motor cortex/corticospinal tract in
99% of patients. In patients with peri-Rolandic brain
tumors, the precision compared to ECS was 6 mm, com-
pared to 10–15 mm for fMRI (Lehericy et al., 2000;
Roessler et al., 2005). It is important to note that there
was no gyral discrepancy (i.e., both TMS and ECS local-
ized the primary motor area to the same gyrus; Picht
et al., 2012; Takahashi et al., 2013). The technique is
better in identifying eloquent areas of the upper extremity
than the lower extremity, due to the location of the hand
motor cortex on the lateral convexity. In a pilot study
(Picht et al., 2013) of navigated TMS for the detection of
eloquent language areas in 20 patients with neoplasms
(n = 18) or cavernomas (n = 2) in the left frontotemporal
areas, navigated TMS produced naming errors in 1–32%
(mean 12%) of 166–683 (mean 450) stimulated locations
per patient. Compared to intraoperative ECS, the tech-
nique identified language areas (i.e., sensitivity) in 90%
(100% of anterior language areas), with a specificity of
24% (13% for the anterior language area; Picht et al.,
2013). This resulted in a positive predictive value of 57%
and a negative predictive value of 100% for identifying
the anterior language area. One patient did not tolerate
navigated TMS at meaningful intensities. It has to be
emphasized that experience of this technique in patients
with pharmacoresistant focal epilepsy is limited (Vitikai-
nen et al., 2009), and more data are needed to define its
role in this setting.
Conclusion
In patients with refractory focal epilepsy due to brain
tumors, functional imaging studies provide noninvasive
information about tumor morphology, treatment response,
and the relationship of tumor tissue to ictal-onset zone and
eloquent areas. This information is helpful in the planning
of tumor biopsies, intracranial EEG evaluations, and
resections. Technologic advances might further improve
identification of FCD and delineation of eloquent cortical
areas.
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